Not applicableStudy completedNCT04071405What this trial is testingKorea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis PatientsWho this might be right forUlcerative Colitis Pfizer 110
Large-scale testing (Phase 3)Ended earlyNCT04477993What this trial is testingRuxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19Who this might be right forSevere Acute Respiratory Syndrome Coronavirus 2SARS-CoV2 Vanderson Geraldo Rocha 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07682792What this trial is testingGolidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaWho this might be right forMycosis Fungoides/Sezary SyndromeT-cell Large Granular Lymphocytic Leukemia Washington University School of Medicine 24
Large-scale testing (Phase 3)Study completedNCT03745651What this trial is testingTRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisWho this might be right forAtopic Dermatitis Incyte Corporation 618
Post-approval studies (Phase 4)Enrolling By InvitationNCT06660329What this trial is testingEfficacy and Safety of Tofacitinib in Refractory Blau SyndromeWho this might be right forBlau Syndrome Peking Union Medical College Hospital 30
Large-scale testing (Phase 3)Study completedNCT04134728What this trial is testingEfficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) InhibitorsWho this might be right forArthritis, Rheumatoid GlaxoSmithKline 550
Not applicableActive Not RecruitingNCT05387980What this trial is testingLearn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.Who this might be right forAtopic Dermatitis Pfizer 1,128
Testing effectiveness (Phase 2)Study completedNCT02997280What this trial is testingRuxolitinib for Steroid-refractory GVHDWho this might be right forGraft Vs Host Disease St. Petersburg State Pavlov Medical University 75
Testing effectiveness (Phase 2)Study completedNCT00147498What this trial is testingThree Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 WeeksWho this might be right forRheumatoid Arthritis Pfizer 264
Testing effectiveness (Phase 2)Study completedNCT02723994What this trial is testingRuxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaWho this might be right forLeukemia Incyte Corporation 171
Early research (Phase 1)Ended earlyNCT03320642What this trial is testingGRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseWho this might be right forHematologic Malignancies Incyte Corporation 84
Early research (Phase 1)Study completedNCT02535689What this trial is testingSafety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusWho this might be right forSystemic Lupus Erythematosus National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574What this trial is testingFlonoltinib Maleate Oral Regimens in Patients With MyelofibrosisWho this might be right forMyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more Chengdu Zenitar Biomedical Technology Co., Ltd 105
Large-scale testing (Phase 3)Looking for participantsNCT06615050What this trial is testingTacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)Who this might be right forGraft-versus-host Disease (GVHD) Incyte Corporation 572
Testing effectiveness (Phase 2)UnknownNCT06244862What this trial is testingJAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care UnitWho this might be right forHemophagocytic Syndromes Assistance Publique - Hôpitaux de Paris 42
Large-scale testing (Phase 3)Study completedNCT01458574What this trial is testingOral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisWho this might be right forUlcerative Colitis Pfizer 593
Large-scale testing (Phase 3)Ended earlyNCT03584516What this trial is testingGRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseWho this might be right forChronic Graft-versus-host Disease Incyte Corporation 155
Large-scale testing (Phase 3)UnknownNCT05451615What this trial is testingEfficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid ArthritisWho this might be right forAbataceptTreatment ComplianceRheumatoid Arthritis Zhejiang Provincial People's Hospital 90
Testing effectiveness (Phase 2)UnknownNCT04640532What this trial is testingKRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFWho this might be right forMyelofibrosisPost-PV MFPost-ET Myelofibrosis+1 more Kartos Therapeutics, Inc. 116
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414What this trial is testingAn Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsWho this might be right forMyeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more Celgene 313